Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

NCT02367872 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda